![Thomas F. Tedder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Thomas F.
Tedder is associated with two companies, Cellective Therapeutics, Inc. and Cellective BioTherapy, Inc. He was the Chief Scientific Officer at Cellective Therapeutics, Inc. from 2003 to 2008.
He is currently the Chief Executive Officer and Director at Cellective BioTherapy, Inc., which he founded in 2015.
Thomas F. Tedder active positions
Companies | Position | Start |
---|---|---|
Cellective BioTherapy, Inc.
![]() Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Founder | 2014-12-31 |
Former positions of Thomas F. Tedder
Companies | Position | End |
---|---|---|
Cellective Therapeutics, Inc.
![]() Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Founder | 2008-11-13 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Cellective Therapeutics, Inc.
![]() Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Health Technology |
Cellective BioTherapy, Inc.
![]() Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Thomas F. Tedder